Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

The grants, awarded in partnership with the Authority of Social Contribution-Ma'an, will fund 11 research projects across multiple disease areas.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.

NEW YORK – Immunocore said last week that it has treated the first patient in a Phase I trial of its bispecific protein therapy IMC-P115C. Through the trial, dubbed IMC-P115C-1005, Oxfordshire, ...